Erratum : Author correction to 'Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects' [Acta Pharmaceutica Sinica B 13 (2023) 2138-2151
© 2023 Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences..
[This corrects the article DOI: 10.1016/j.apsb.2022.12.009.].
| Errataetall: |
ErratumFor: Acta Pharm Sin B. 2023 May;13(5):2138-2151. - PMID 37250154 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Acta pharmaceutica Sinica. B - 14(2024), 3 vom: 15. März, Seite 1477 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wei, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 15.03.2024 published: Print-Electronic ErratumFor: Acta Pharm Sin B. 2023 May;13(5):2138-2151. - PMID 37250154 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.apsb.2023.12.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369766733 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369766733 | ||
| 003 | DE-627 | ||
| 005 | 20240315234702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.apsb.2023.12.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1330.xml |
| 035 | |a (DE-627)NLM369766733 | ||
| 035 | |a (NLM)38486984 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wei, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Erratum |b Author correction to 'Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects' [Acta Pharmaceutica Sinica B 13 (2023) 2138-2151 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumFor: Acta Pharm Sin B. 2023 May;13(5):2138-2151. - PMID 37250154 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. | ||
| 520 | |a [This corrects the article DOI: 10.1016/j.apsb.2022.12.009.] | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Zeng, Qingxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Xixi |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Tianyun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yinghong |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Hongbin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xintong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yonghua |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Yulong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Jingyang |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Xican |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jiandong |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Danqing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica Sinica. B |d 2012 |g 14(2024), 3 vom: 15. März, Seite 1477 |w (DE-627)NLM227628217 |x 2211-3835 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:3 |g day:15 |g month:03 |g pages:1477 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.apsb.2023.12.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 3 |b 15 |c 03 |h 1477 | ||